Literature DB >> 22878281

Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance.

Go-Eun Choi1, Sung Jae Shin, Choul-Jae Won, Ki-Nam Min, Taegwon Oh, Mi-Young Hahn, Keehoon Lee, Soo Hyun Lee, Charles L Daley, Seonwoo Kim, Byeong-Ho Jeong, Kyeongman Jeon, Won-Jung Koh.   

Abstract

RATIONALE: Macrolides, such as clarithromycin (CLR) and azithromycin (AZM), are frequently the only oral antibiotics that are active against Mycobacterium abscessus and M. massiliense infections.
OBJECTIVES: To compare the activity of CLR and AZM in experimental models.
METHODS: We compared the treatment efficacies of CLR and AZM and determined the correlation between efficacy and induced erythromycin ribosome methyltransferase gene (erm)(41) expression in experimental models of M. abscessus and M. massiliense infections.
MEASUREMENTS AND MAIN RESULTS: In all tested M. abscessus isolates, a high level of inducible CLR resistance developed (minimal inhibitory concentration [MIC] on Day 3 versus Day 14; P < 0.001). Whereas the AZM MIC increased on Day 14 (P < 0.01 versus Day 3), the level was significantly lower than the CLR MIC on Day 14 (P < 0.001). However, the MICs of CLR and AZM for the M. massiliense isolates did not change. Compared with CLR, AZM presented greater antibiotic activity against M. abscessus in vitro, ex vivo, and in vivo (P < 0.05), whereas both macrolides were comparably effective against M. massiliense. In M. abscessus infection, the level of erm(41) expression was higher after exposure to CLR than after exposure to AZM (P < 0.001). Experiments using an erm(41)-knockout M. abscessus mutant and an M. massiliense transformant expressing M. abscessus erm(41) confirmed that erm(41) was responsible for inducible CLR resistance.
CONCLUSIONS: CLR induces greater erm(41) expression and thus higher macrolide resistance than AZM in M. abscessus infection. AZM may be more effective against M. abscessus, whereas both macrolides appear to be equally effective against M. massiliense.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22878281     DOI: 10.1164/rccm.201111-2005OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  61 in total

1.  Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.

Authors:  Valerie Waters; Felix Ratjen
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

2.  Invasive Mycobacterium abscessus Complex Infection After Cardiac Surgery: Epidemiology, Management, and Clinical Outcomes.

Authors:  Arthur W Baker; Eileen K Maziarz; Sarah S Lewis; Jason E Stout; Deverick J Anderson; Peter K Smith; Jacob N Schroder; Mani A Daneshmand; Barbara D Alexander; Richard J Wallace; Daniel J Sexton; Cameron R Wolfe
Journal:  Clin Infect Dis       Date:  2021-04-08       Impact factor: 9.079

3.  Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others.

Authors:  Jason E Stout; R Andres Floto
Journal:  Am J Respir Crit Care Med       Date:  2012-11-01       Impact factor: 21.405

4.  Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only.

Authors:  W-J Koh; K Jeon; S J Shin
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

5.  Management of a Mycobacterium immunogenum infection of a peritoneal dialysis catheter site.

Authors:  Abhishek Shenoy; Walid El-Nahal; McCall Walker; Tushar Chopra; Gregory Townsend; Scott Heysell; Joshua Eby
Journal:  Infection       Date:  2018-08-21       Impact factor: 3.553

6.  Mycobacterium abscessus Displays Fitness for Fomite Transmission.

Authors:  Kenneth C Malcolm; Silvia M Caceres; Jennifer R Honda; Rebecca M Davidson; L Elaine Epperson; Michael Strong; Edward D Chan; Jerry A Nick
Journal:  Appl Environ Microbiol       Date:  2017-09-15       Impact factor: 4.792

7.  Mycobacterium abscessus Lung Infection: A Case Report.

Authors:  Pan Pan Wang; Charles-André Bray; Simon Grandjean Lapierre; Hafid Soualhine; Fanny Arbour
Journal:  Can J Hosp Pharm       Date:  2016-06-30

Review 8.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

9.  Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease.

Authors:  Jennifer Adjemian; D Rebecca Prevots; Jack Gallagher; Kylee Heap; Renu Gupta; David Griffith
Journal:  Ann Am Thorac Soc       Date:  2014-01

10.  Discrimination of Mycobacterium abscessus subsp. massiliense from Mycobacterium abscessus subsp. abscessus in clinical isolates by multiplex PCR.

Authors:  Kazue Nakanaga; Tsuyoshi Sekizuka; Hanako Fukano; Yumi Sakakibara; Fumihiko Takeuchi; Shinpei Wada; Norihisa Ishii; Masahiko Makino; Makoto Kuroda; Yoshihiko Hoshino
Journal:  J Clin Microbiol       Date:  2013-11-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.